Invesaro

Stocks APTN Financial statements

Financial statements

ADAPTIN BIO, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data ADAPTIN BIO, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2023FY2024FY2025
Research and development1.821.77
General and administrative0.090.753.64
Operating expenses2.575.41
Operating income-0.09-2.57-5.41
Interest expense0.340.07
Other non-operating income-0.550.25
Pre-tax income-3.12-5.17
Net income-0.09-3.12-5.17
EPS, basic-0.51-0.96-0.66
EPS, diluted-0.51-0.96-0.66
Shares, basic (weighted)0.173.257.81
Shares, diluted (weighted)0.173.257.81

Balance sheet

FY2023FY2024FY2025
Cash and equivalents00.030.46
Other current assets0.010.16
Total current assets00.050.62
Total assets00.240.62
Accounts payable01.361.51
Accrued liabilities1.050.6
Total current liabilities0.114.342.11
Total liabilities0.114.342.11
Paid-in capital0.027.8
Retained earnings-0.11-4.12-9.29
Shareholders' equity-0.98-4.1-1.49
Total equity-0.98-4.1-1.49
Total liabilities and equity00.240.62
Shares outstanding0.173.258.66

Cash flow statement

FY2023FY2024FY2025
Net income-0.09-3.12-5.17
Stock-based compensation0.5
Change in payables-0.010.85-0.45
Cash from operations-0.08-0.65-4.78
Cash from financing0.080.685.2
Net change in cash-00.030.43
Interest paid0.01
Income taxes paid000

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.27 on August 19, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-549.7%Net income / average total assets.

Growth

MetricValueHow it is calculated
Total assets growth, 1y158.6%Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y140.4%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.37xCurrent assets / current liabilities.
Quick ratio0.25x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.25x(Cash + short-term investments) / current liabilities.
Liabilities / assets269.7%Total liabilities / total assets.
Interest coverage-812xOperating income / interest expense.
Working capital-$1.7MCurrent assets - current liabilities.
Tangible book value-$1.7MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$0.61Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share-$0.28Cash from operations / diluted weighted shares.
Book value per share-$0.18Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$0.18Tangible book value / shares outstanding.
Cash per share$0.07(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$57.9MShare price x shares outstanding.
Enterprise value$57.2MMarket cap + total debt - cash - short-term investments.
Earnings yield-9.3%Net income / market cap (the inverse of P/E).
Was ADAPTIN BIO, INC. profitable in fiscal 2025?

No. It reported a net loss of $5.2M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to ADAPTIN BIO, INC.